Emerging Immunotherapy for Acute Myeloid Leukemia.

Area of Science:

• Oncology
• Immunology

Background:

• Acute myeloid leukemia (AML) remains a challenging hematologic malignancy.
• Immuno-oncology (IO) therapies are emerging as a promising treatment modality for AML.
• Key targets include CD33, CD123, and CLL-1, alongside immune checkpoint inhibitors like anti-PD-1 and anti-CTLA4.

Purpose of the Study:

• To summarize the current advantages and clinical benefits of IO therapy in treating AML.
• To review various IO approaches, including CAR-T/NK cells, bispecific antibodies, and checkpoint inhibitors.

Main Methods:

• Review of early-phase clinical trials and existing literature on IO therapies for AML.
• Analysis of treatment outcomes, including complete remission (CR) rates and survival data.
• Assessment of adverse events such as cytokine-releasing syndrome (CRS).

Main Results:

• Chimeric antigen receptor (CAR)-T and natural killer (NK) cells showed complete remission (CR) in some relapsed/refractory AML patients.
• Bispecific antibodies achieved CR rates of 11-67% but carried a risk of cytokine-releasing syndrome (CRS) (13-78%).
• Combination chemotherapy with anti-PD-1/anti-CTLA4 antibodies resulted in 10-36% CR rates and a median survival of 7-24 months.

Conclusions:

• IO therapies, including targeted agents and checkpoint inhibitors, offer significant potential for managing AML.
• While promising, further research is needed to optimize efficacy and manage toxicities associated with these novel treatments.
• Cancer vaccination, a component of IO, was excluded due to limited evidence in AML.